CASE REPORT
Published on 02 Apr 2025
Anlotinib induced type 1 diabetes: a case report
doi 10.3389/fonc.2025.1508645
- 523 views
- Frontiers in Oncology
- Pharmacology of Anti-Cancer Drugs
- Research Topics
- EGFR-TKIs for Lung Cancer Treatment: Development, Application, and Side Effects
EGFR-TKIs for Lung Cancer Treatment: Development, Application, and Side Effects
5,795
Total downloads
20k
Total views and downloads
Articles
ORIGINAL RESEARCH
Published on 11 Mar 2025
Adverse event profiles of EGFR-TKI: network meta-analysis and disproportionality analysis of the FAERS database
doi 10.3389/fphar.2025.1519849
- 854 views
ORIGINAL RESEARCH
Published on 20 Feb 2025
Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study
doi 10.3389/fonc.2025.1506041
- 1,273 views
CASE REPORT
Published on 18 Feb 2025
Case report: A patient with EGFR L861Q positive adenosquamous lung carcinoma transforming into large cell neuroendocrine cancer after treatment with Almonertinib
doi 10.3389/fonc.2025.1453066
- 657 views
CASE REPORT
Published on 17 Feb 2025
Almonertinib-induced interstitial lung disease in an NSCLC patient co-harboring EGFR Ex19del mutation and MET de novo amplification: a case report and literature review
doi 10.3389/fonc.2025.1481244
- 560 views
- 1 citation
SYSTEMATIC REVIEW
Published on 29 Jan 2025
Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks
doi 10.3389/fphar.2025.1491990
- 899 views
SYSTEMATIC REVIEW
Published on 23 Dec 2024
Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis
doi 10.3389/fimmu.2024.1512468
- 1,527 views
CASE REPORT
Published on 17 Dec 2024
A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review
doi 10.3389/fonc.2024.1467722
- 1,149 views
ORIGINAL RESEARCH
Published on 12 Dec 2024
Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with Her-2 overexpression
doi 10.3389/fonc.2024.1472545
- 538 views
ORIGINAL RESEARCH
Published on 06 Sep 2024
Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study
doi 10.3389/fphar.2024.1444707
- 1,187 views
CASE REPORT
Published on 21 Aug 2024
Potential therapeutic option for EGFR-mutant small cell lung cancer transformation: a case report and literature review
doi 10.3389/fimmu.2024.1439033
- 2,338 views
- 1 citation
ORIGINAL RESEARCH
Published on 25 Jul 2024
Identification of potential inhibitors for drug-resistant EGFR mutations in non-small cell lung cancer using whole exome sequencing data
doi 10.3389/fphar.2024.1428158
- 1,492 views
- 2 citations
Published in
Frontiers in Oncology
Pharmacology of Anti-Cancer Drugs
Participating Journals
Frontiers in Pharmacology
- 4.4 impact factor
- 7.8 citescore